In newly diagnosed chronic phase Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia patients, imatinib-resistant BCR-ABL mutations are already detectable at low levels but do not correlate with subsequent clinical outcome – A study by the GIMEMA ALL and GIMEMA CML Working Parties.